# A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

> **NCT01130623** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Sarcoma
- Neuroblastoma
- Wilms Tumor
- Osteosarcoma
- Brain Tumor

## Interventions

- **DRUG:** Pazopanib (GW786034)

## Key facts

- **NCT ID:** NCT01130623
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-05-10
- **Primary completion:** 2011-11-18
- **Final completion:** 2011-11-18
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130623, "A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01130623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*